April 29, 2026. Avelo AG is pleased to share that Prof. Dr. Michael Osthoff from University Hospital Basel presented real-world clinical results for AveloMask at ESCMID Global 2026 in Munich, one of the world's leading conferences in clinical microbiology and infectious diseases. The data, generated in a prospective two-center study (AeroCAP) with 63 adults with confirmed lower respiratory tract infections (LRTIs), showed that AveloMask breath aerosol PCR: Detected the domina

March 24, 2026. Avelo is pleased to announce new research results presented at the Annual Meeting of the German Society for Virology (GfV). The study, conducted by the Institute of Medical Virology at Goethe University Frankfurt (Ciesek group), establishes a robust laboratory workflow for detecting respiratory viruses using the AveloMask Kit. The research successfully integrated AveloMask breath samples into widely adopted diagnostic platforms , including QIAsymphony (Qiagen)

February 25, 2026. Avelo AG is pleased to announce that results from a clinical study evaluating the AveloMask Kit for detection of Pseudomonas aeruginosa in adults with Cystic Fibrosis (CF) were presented at the DZIF Annual Meeting in Bonn by researchers from Heidelberg University Hospital. The study assessed non-invasive exhaled breath aerosol sampling using the AveloMask Kit as an alternative to sputum collection. New, highly effective CFTR-modulator therapies significant

November 21, 2025. Avelo is pleased to share that partners from the CLIME Research Group at Stellenbosch University presented the latest AveloMask Kit tuberculosis (TB) study results today at the Union Conference in Copenhagen, a leading global forum for TB and the world’s largest conference on lung health. A short video summarizing the study results is available here: The study showcases the feasibility and diagnostic potential of capturing Mycobacterium tuberculosis from